JP2023518066A5 - - Google Patents
Info
- Publication number
- JP2023518066A5 JP2023518066A5 JP2022556091A JP2022556091A JP2023518066A5 JP 2023518066 A5 JP2023518066 A5 JP 2023518066A5 JP 2022556091 A JP2022556091 A JP 2022556091A JP 2022556091 A JP2022556091 A JP 2022556091A JP 2023518066 A5 JP2023518066 A5 JP 2023518066A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical preparation
- concentration
- arginine
- histidine
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025064827A JP2025111516A (ja) | 2020-03-20 | 2025-04-10 | 高濃度抗Ａβプロトフィブリル抗体製剤及びその使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062992746P | 2020-03-20 | 2020-03-20 | |
| US62/992,746 | 2020-03-20 | ||
| US202063027263P | 2020-05-19 | 2020-05-19 | |
| US63/027,263 | 2020-05-19 | ||
| PCT/IB2021/000155 WO2021186245A1 (en) | 2020-03-20 | 2021-03-19 | HIGH CONCENTRATION ANTI-Aß PROTOFIBRIL ANTIBODY FORMULATIONS AND METHODS OF USE THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025064827A Division JP2025111516A (ja) | 2020-03-20 | 2025-04-10 | 高濃度抗Ａβプロトフィブリル抗体製剤及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023518066A JP2023518066A (ja) | 2023-04-27 |
| JP2023518066A5 true JP2023518066A5 (https=) | 2024-10-08 |
| JP7689141B2 JP7689141B2 (ja) | 2025-06-05 |
Family
ID=75746958
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022556091A Active JP7689141B2 (ja) | 2020-03-20 | 2021-03-19 | 高濃度抗Ａβプロトフィブリル抗体製剤及びその使用方法 |
| JP2025064827A Pending JP2025111516A (ja) | 2020-03-20 | 2025-04-10 | 高濃度抗Ａβプロトフィブリル抗体製剤及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025064827A Pending JP2025111516A (ja) | 2020-03-20 | 2025-04-10 | 高濃度抗Ａβプロトフィブリル抗体製剤及びその使用方法 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20230183328A1 (https=) |
| EP (2) | EP4121007B1 (https=) |
| JP (2) | JP7689141B2 (https=) |
| KR (1) | KR20220156534A (https=) |
| CN (1) | CN115315251A (https=) |
| AU (1) | AU2021238951A1 (https=) |
| BR (1) | BR112022018766A2 (https=) |
| CA (1) | CA3174778A1 (https=) |
| CL (2) | CL2022002517A1 (https=) |
| CO (1) | CO2022012916A2 (https=) |
| DK (1) | DK4121007T3 (https=) |
| ES (1) | ES3041762T3 (https=) |
| FI (1) | FI4121007T3 (https=) |
| HR (1) | HRP20251087T1 (https=) |
| HU (1) | HUE072937T2 (https=) |
| IL (2) | IL295383B1 (https=) |
| LT (1) | LT4121007T (https=) |
| MA (1) | MA59082B1 (https=) |
| MD (1) | MD4121007T2 (https=) |
| MX (1) | MX2022011101A (https=) |
| PH (1) | PH12022552172A1 (https=) |
| PL (1) | PL4121007T3 (https=) |
| PT (1) | PT4121007T (https=) |
| RS (1) | RS67249B1 (https=) |
| SI (1) | SI4121007T1 (https=) |
| SM (1) | SMT202500350T1 (https=) |
| WO (1) | WO2021186245A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230039734A (ko) | 2020-07-23 | 2023-03-21 | 오타이르 프로테나 리미티드 | 항-Aβ 항체 |
| AU2022307687A1 (en) | 2021-07-09 | 2024-01-04 | Eisai R&D Management Co., Ltd. | Biomarkers for alzheimer's disease treatment |
| AU2022439338A1 (en) | 2022-02-02 | 2024-08-15 | Eisai R&D Management Co., Ltd. | Methods of treatment using p-tau181 level |
| JP2025539394A (ja) | 2022-11-28 | 2025-12-05 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | タウｐｅｔレベルを使用する治療の方法 |
| KR20260022396A (ko) | 2023-06-09 | 2026-02-19 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 항-Aβ 프로토피브릴 항체를 사용한 치료 방법 |
| WO2026015877A1 (en) | 2024-07-12 | 2026-01-15 | Eisai R&D Management Co., Ltd. | Fluid biomarker |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20091174A1 (es) * | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| CN118370815A (zh) | 2017-08-22 | 2024-07-23 | 渤健马萨诸塞州股份有限公司 | 含有抗β淀粉样蛋白抗体的药物组合物 |
| US20210324056A1 (en) | 2018-07-24 | 2021-10-21 | Eisai R&D Management Co., Ltd. | Methods of treatment and prevention of alzheimer's disease |
-
2021
- 2021-03-19 RS RS20250922A patent/RS67249B1/sr unknown
- 2021-03-19 EP EP21722538.2A patent/EP4121007B1/en active Active
- 2021-03-19 BR BR112022018766A patent/BR112022018766A2/pt unknown
- 2021-03-19 KR KR1020227030919A patent/KR20220156534A/ko active Pending
- 2021-03-19 PL PL21722538.2T patent/PL4121007T3/pl unknown
- 2021-03-19 MX MX2022011101A patent/MX2022011101A/es unknown
- 2021-03-19 IL IL295383A patent/IL295383B1/en unknown
- 2021-03-19 FI FIEP21722538.2T patent/FI4121007T3/fi active
- 2021-03-19 WO PCT/IB2021/000155 patent/WO2021186245A1/en not_active Ceased
- 2021-03-19 CN CN202180019180.6A patent/CN115315251A/zh active Pending
- 2021-03-19 PH PH1/2022/552172A patent/PH12022552172A1/en unknown
- 2021-03-19 AU AU2021238951A patent/AU2021238951A1/en active Pending
- 2021-03-19 US US17/906,660 patent/US20230183328A1/en active Pending
- 2021-03-19 MD MDE20230104T patent/MD4121007T2/ro unknown
- 2021-03-19 SI SI202130347T patent/SI4121007T1/sl unknown
- 2021-03-19 PT PT217225382T patent/PT4121007T/pt unknown
- 2021-03-19 IL IL326613A patent/IL326613A/en unknown
- 2021-03-19 DK DK21722538.2T patent/DK4121007T3/da active
- 2021-03-19 EP EP23179487.6A patent/EP4252777A3/en active Pending
- 2021-03-19 SM SM20250350T patent/SMT202500350T1/it unknown
- 2021-03-19 JP JP2022556091A patent/JP7689141B2/ja active Active
- 2021-03-19 HU HUE21722538A patent/HUE072937T2/hu unknown
- 2021-03-19 LT LTEPPCT/IB2021/000155T patent/LT4121007T/lt unknown
- 2021-03-19 MA MA59082A patent/MA59082B1/fr unknown
- 2021-03-19 HR HRP20251087TT patent/HRP20251087T1/hr unknown
- 2021-03-19 CA CA3174778A patent/CA3174778A1/en active Pending
- 2021-03-19 ES ES21722538T patent/ES3041762T3/es active Active
-
2022
- 2022-09-12 CO CONC2022/0012916A patent/CO2022012916A2/es unknown
- 2022-09-14 CL CL2022002517A patent/CL2022002517A1/es unknown
-
2024
- 2024-11-08 CL CL2024003428A patent/CL2024003428A1/es unknown
-
2025
- 2025-04-10 JP JP2025064827A patent/JP2025111516A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023518066A5 (https=) | ||
| IL295383A (en) | High concentration anti-aß protofibril antibody formulations and methods of use thereof | |
| JP2024075713A5 (https=) | ||
| JP2021155453A5 (https=) | ||
| JP2020518599A5 (https=) | ||
| AR127344A2 (es) | Conjugados anticuerpo-fármaco que comprenden agonistas de sting | |
| JP2006516262A5 (https=) | ||
| JP2013512889A5 (https=) | ||
| FI3644999T3 (fi) | 2-(4-kloorifenyyli)-n-((2-(2,6-dioksopiperidin-3-yyli)-1-oksoisoindolin-5-yyli)metyyli)-2,2-difluoriasetamidin koostumukset ja menetelmät sen käyttämiseksi | |
| JP2013500947A5 (https=) | ||
| JP2021519076A5 (https=) | ||
| HRP20120893T1 (hr) | Formulacija protutijela na histidin-acetatnom puferu | |
| FI3672631T3 (fi) | Beeta-amyloidin vasta-aineita sisältäviä lääkekoostumuksia | |
| JP2012520882A5 (https=) | ||
| JP2003525240A (ja) | 糖尿病性腎障害の処置のためのｐｄｇｆ受容体チロシンキナーゼ阻害剤の使用 | |
| JP2020532562A5 (https=) | ||
| RU2018129077A (ru) | Стабильная фармацевтическая композиция | |
| US20240082195A1 (en) | Compositions for treating fungal and bacterial biofilms and methods of using the same | |
| JP2024540377A5 (https=) | ||
| JP2024540395A5 (https=) | ||
| CN115803055A (zh) | 一种抗pd-1单克隆抗体液体制剂 | |
| IL276911B1 (en) | Variants of the carboxylation rate of antibodies | |
| EA200501129A1 (ru) | Парентеральные композиции пептида для лечения системной красной волчанки | |
| JP2022519796A5 (https=) | ||
| JP2023502398A5 (https=) |